Burning Rock Biotech vs Harvard Bioscience
Harvard Bioscience is the larger business, with $86.5m of revenue in fiscal 2025 against $75.1m for Burning Rock Biotech (1.2 times as much). Burning Rock Biotech grew faster (4.7% against -8.1%). Burning Rock Biotech kept more of each dollar of sales as profit: a net margin of -10.3% against -65.5%.
| Latest fiscal year | Burning Rock BiotechBNR, 2025 | Harvard BioscienceHBIO, 2025 |
|---|---|---|
| Revenue | $75.1m | $86.5m |
| Revenue growth | 4.7% | -8.1% |
| Net income | −$7.7m | −$56.7m |
| Operating margin | — | -56.1% |
| Net margin | -10.3% | -65.5% |
| Return on equity | -9.9% | -147.1% |
| Free cash flow | −$4.7m | $5.5m |
| Cash | $68.4m | $8.6m |
| Total debt | $243,097 | $40.0m |
| Debt to equity | — | 291.2% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 339 |
| Market value | $115m | $40.1m |
| Price vs our value range | — | — |
| Moat score | — | 56 (Moderate) |
| Insider trades, 12 months | 8 buys, 0 sales | 5 buys, 0 sales |